Ranbaxy Lab gains even as US court rejects co’s appeal to block ANDA nod for 2 drugs

27 Nov 2014 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 620.00, up by 4.55 points or 0.74% from its previous closing of Rs. 615.45 on the BSE.

The scrip opened at Rs. 611.10 and has touched a high and low of Rs. 621.75 and Rs. 611.10 respectively. So far 52298 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 697.50 on 10-Nov-2014 and a 52 week low of Rs. 306.05 on 27-Jan-2014.

Last one week high and low of the scrip stood at Rs. 631.00 and Rs. 587.00 respectively. The current market cap of the company is Rs. 26353.24 crore.

The promoters holding in the company stood at 63.37 % while Institutions and Non-Institutions held 21.49 % and 13.73 % respectively.

DC Federal Court in the US has not granted Ranbaxy Laboratories' temporary restraining order to block the US health regulator from approving other ANDAs for generic versions of digestive disorder medicine Nexium and anti-viral Valcyte. However, the court ordered the parties to the suit to agree upon a schedule for filing additional legal briefs, addressing Ranbaxy’s request for a preliminary injunction by November 21, 2014. Earlier, the company had filed a complaint against the US FDA in D.C. Federal Court and had also asked the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided.

Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1519.20
Dr. Reddys Lab 6241.40
Cipla 1415.15
Zydus Lifesciences 966.55
Lupin 1654.80
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.